JP2011088897A5 - - Google Patents

Download PDF

Info

Publication number
JP2011088897A5
JP2011088897A5 JP2010253233A JP2010253233A JP2011088897A5 JP 2011088897 A5 JP2011088897 A5 JP 2011088897A5 JP 2010253233 A JP2010253233 A JP 2010253233A JP 2010253233 A JP2010253233 A JP 2010253233A JP 2011088897 A5 JP2011088897 A5 JP 2011088897A5
Authority
JP
Japan
Prior art keywords
apo
ligand
formulation
metal ions
divalent metal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010253233A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011088897A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011088897A publication Critical patent/JP2011088897A/ja
Publication of JP2011088897A5 publication Critical patent/JP2011088897A5/ja
Pending legal-status Critical Current

Links

JP2010253233A 1999-06-28 2010-11-11 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法 Pending JP2011088897A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14134299P 1999-06-28 1999-06-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2001506824A Division JP5118796B2 (ja) 1999-06-28 2000-06-26 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法

Publications (2)

Publication Number Publication Date
JP2011088897A JP2011088897A (ja) 2011-05-06
JP2011088897A5 true JP2011088897A5 (enExample) 2012-02-02

Family

ID=22495287

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001506824A Expired - Lifetime JP5118796B2 (ja) 1999-06-28 2000-06-26 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法
JP2010253233A Pending JP2011088897A (ja) 1999-06-28 2010-11-11 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2001506824A Expired - Lifetime JP5118796B2 (ja) 1999-06-28 2000-06-26 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法

Country Status (12)

Country Link
US (3) US7855066B1 (enExample)
EP (3) EP1194555B1 (enExample)
JP (2) JP5118796B2 (enExample)
KR (1) KR100674528B1 (enExample)
CN (2) CN100526463C (enExample)
AU (3) AU6338200A (enExample)
CA (1) CA2377585A1 (enExample)
ES (1) ES2392392T3 (enExample)
IL (2) IL147029A0 (enExample)
MX (1) MXPA01013236A (enExample)
NZ (2) NZ515990A (enExample)
WO (1) WO2001000832A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020106728A1 (en) * 2000-06-20 2002-08-08 Genentech, Inc. NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
EP1820860A3 (en) * 1999-06-02 2008-03-19 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
EP1194555B1 (en) * 1999-06-28 2012-09-26 Genentech, Inc. Methods for making apo-2 ligand using divalent metal ions
EP2348043A1 (en) * 2001-10-02 2011-07-27 Genentech, Inc. APO-2 ligand variants and uses thereof
CA2466054C (en) 2001-11-13 2012-01-03 Genentech, Inc. Apo-2 ligand/trail formulations
AU2007200478A1 (en) * 2001-11-13 2007-02-22 Genentech, Inc. APO2 ligand/trail formulations
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
US7741285B2 (en) * 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
WO2004001009A2 (en) * 2002-06-24 2003-12-31 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
GB0328261D0 (en) * 2003-12-05 2004-01-07 Univ Groningen Improved cytokine design
BRPI0507233B8 (pt) 2004-03-11 2021-05-25 Genentech Inc processo para a produção de um polipeptídeo heterólogo em e. coli
CN101061238B (zh) 2004-08-06 2013-11-20 健泰科生物技术公司 使用生物标志的测定法和方法
ES2365719T3 (es) 2004-08-06 2011-10-10 Genentech, Inc. Ensayos y procedimientos que utilizan biomarcadores.
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
BRPI0615997A8 (pt) 2005-08-16 2018-05-22 Genentech Inc método para prever a sensibilidade de uma amostra de célula ou tecido, método para induzir apoptose em uma amostra de célula ou tecido e método de tratamento de uma disfunção
GB0524316D0 (en) * 2005-11-29 2006-01-04 Medical Res Council Tumour necrosis factor-related apoptosis-inducing ligands (TRAILs)
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
WO2012151317A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Vascular disruption agents and uses thereof
CN102775491A (zh) * 2011-05-09 2012-11-14 中国人民解放军第二军医大学 单链化的人凋亡素2配体三聚体蛋白质的制法和用途
CN102443055B (zh) * 2011-10-26 2017-07-28 浙江海正药业股份有限公司 一种重组人肿瘤坏死因子相关凋亡诱导配体的纯化工艺
JP6355425B2 (ja) * 2014-05-20 2018-07-11 キヤノン株式会社 システムおよびその制御方法
US11279768B1 (en) 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
US10906951B2 (en) * 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
AU2017234679A1 (en) * 2016-03-16 2018-08-30 Merrimack Pharmaceuticals, Inc. Engineered trail for cancer therapy
JP7257345B2 (ja) * 2019-04-04 2023-04-13 株式会社オハラ 光学ガラスの製造方法
JP7429622B2 (ja) * 2020-08-26 2024-02-08 株式会社オハラ 光学ガラスの製造方法
CN115980241B (zh) * 2023-02-11 2025-01-07 烟台新特路新材料科技有限公司 一种硫代酯类抗氧化剂含量的检测方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
ES2032831T5 (es) 1986-08-19 2001-02-16 Genentech Inc Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
JPH04501201A (ja) 1987-12-21 1992-03-05 ジ・アップジョン・カンパニー 発芽植物種子類のアグロバクテリウム媒介形質転換
US6063763A (en) * 1989-04-28 2000-05-16 Schering Aktiengesellschaft Protease-resistant thrombomodulin analogs
DK168302B1 (da) 1989-06-29 1994-03-07 Danisco Fremgangsmåde til indføring af molekyler, især genetisk materiale i planteceller
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
WO1992003478A1 (en) 1990-08-17 1992-03-05 Genentech, Inc. Metal ion mediated receptor binding of polypeptide hormones
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
WO1992017200A2 (en) 1991-03-28 1992-10-15 Genentech, Inc. Stable growth hormone metal ion formulations
US6387650B1 (en) * 1995-06-07 2002-05-14 Biocontrol Systems, Inc. Method and composition for detecting bacterial contamination in food products
CA2225378C (en) * 1995-06-29 2012-04-17 Immunex Corporation Cytokine that induces apoptosis
DE19547933A1 (de) * 1995-12-22 1997-06-26 Boehringer Mannheim Gmbh Multimere Formen von IL-16, Verfahren zu ihrer Herstellung und Verwendung
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
AU3381097A (en) 1996-06-07 1998-01-05 Amgen, Inc. Tumor necrosis factor-related polypeptide
WO1998014577A2 (en) 1996-10-03 1998-04-09 Biotherapies, Inc. Nucleotide and protein sequence of mammastatin and methods of use
NZ334309A (en) 1996-10-25 2000-08-25 Human Genome Sciences Inc Neutrokine alpha protein, a member of the TNF family, and its use in treating and/or detecting immune disorders
ATE497001T1 (de) 1996-12-23 2011-02-15 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
EA003636B1 (ru) 1997-04-16 2003-08-28 Амген Инк. Остеопротегеринсвязующие белки и рецепторы
PT981618E (pt) 1997-05-15 2007-11-23 Genentech Inc ''anticorpo anti-apo-2''
AU8485098A (en) 1997-08-26 1999-03-16 Genentech Inc. Rtd receptor
CA2318029C (en) * 1998-01-15 2009-05-19 Genentech, Inc. Apo-2 ligand
SE9802454D0 (sv) 1998-07-08 1998-07-08 Pharmacia & Upjohn Ab Production of peptides
EP1194555B1 (en) * 1999-06-28 2012-09-26 Genentech, Inc. Methods for making apo-2 ligand using divalent metal ions
AU7053000A (en) 1999-09-10 2001-04-10 Eli Lilly And Company Flint compounds and formulations thereof
AU6891800A (en) 1999-09-10 2001-04-10 Eli Lilly And Company Flint analog compounds and formulations thereof
EP2348043A1 (en) * 2001-10-02 2011-07-27 Genentech, Inc. APO-2 ligand variants and uses thereof
CA2466054C (en) * 2001-11-13 2012-01-03 Genentech, Inc. Apo-2 ligand/trail formulations
CN100500841C (zh) * 2005-10-10 2009-06-17 华东理工大学 一种表达可溶性trail蛋白的方法

Similar Documents

Publication Publication Date Title
JP2013522425A5 (enExample)
JP2011506530A5 (enExample)
JP2013546230A5 (enExample)
JP2013540852A5 (enExample)
CN102036649A8 (zh) 精氨酸盐及其治疗口腔疾病的用途
JP2014500291A5 (enExample)
EP2652711A4 (en) Coordination of animations between multiple applications or processes
JP2013140343A5 (enExample)
JP2013249393A5 (enExample)
JP2011510778A5 (enExample)
JP2012516348A5 (enExample)
MY173847A (en) Disinfectant compositions and uses thereof
WO2015038689A3 (en) Cationic antiseptic compositions
WO2010042633A3 (en) Naringenin complexes and methods of use thereof
MX2013008277A (es) Composicion liquida y acousa de bromfenaco, que tiene efectividad conservadora.
JP2012532753A5 (enExample)
JP2011104357A5 (enExample)
EP2628485A4 (en) New use of chemical ingredients in cynomorium as phytoestrogen
Doi et al. A two-country dynamic model of international trade and endogenous growth: Multiple balanced growth paths and stability
JP2011008097A5 (enExample)
SI2699545T1 (sl) Novi amino-pirolinski derivati in uporaba le-teh pri preprečevanju in/ali zdravljenju metaboličnega sindroma
PL392957A1 (pl) Preparat zawierający dodatek zoohigieniczny poprawiający warunki zoohigieniczne w pomieszczeniach gospodarskich i zastosowanie preparatu
CL2013001596A1 (es) Proceso de purificacion y estabilizacion de la enzima gluconato deshidrogenasa (gadh, ec 1.1.99.3); enzima gluconato deshidrogenasa (gadh, ec 1.1.99.3); y uso de la enzima gluconato deshidrogenasa (gadh, ec 1.1.99.3).
EP2353384A3 (en) Disinfectant formulations that remain liquid at low temperature
Iwasaka et al. Processes of background KOSA outbreak: Lidar and balloon-borne measurements